WALTHAM, Mass., April 16, 2010 /PRNewswire via COMTEX/ -- Repligen Corporation
.../...
HDAC-3 Inhibitors for Friedreich's Ataxia
We are currently developing inhibitors of histone deacetylase 3 (HDAC-3) for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. Preclinical studies have shown that specific HDAC-3 inhibitors increase production of the protein frataxin which may have the potential to arrest disease progression in patients with Friedreich's ataxia. We plan to file an Investigational New Drug Application (IND) for a Phase 1 human clinical study of RG2833 in healthy volunteers this quarter.
.../...
Saturday, April 17, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment